Seer (NASDAQ:SEER) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Seer (NASDAQ:SEER) posted its quarterly earnings data on Tuesday. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01, FiscalAI reports. Seer had a negative return on equity of 27.23% and a negative net margin of 478.05%. The firm had revenue of $3.98 million during the quarter, compared to the consensus estimate of $4.15 million.

Seer Stock Performance

SEER traded down $0.07 during trading on Tuesday, hitting $1.61. The stock had a trading volume of 125,604 shares, compared to its average volume of 521,158. The firm has a market capitalization of $89.15 million, a P/E ratio of -1.32 and a beta of 1.49. The company’s 50-day moving average price is $1.97 and its 200 day moving average price is $1.91. Seer has a twelve month low of $1.55 and a twelve month high of $2.38.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $4.00.

Seer Company Profile

Seer, Inc. is a life sciences company that develops technologies for large-scale protein analysis, known as proteomics. The company’s platform is designed to help researchers study a broad range of proteins in biological samples and generate detailed information that may support drug discovery, disease research and biomarker development. Seer’s primary offering is the Proteograph Product Suite, which combines engineered nanoparticle technology, laboratory consumables, automation and software. The system is intended to provide deep, unbiased proteomic analysis from relatively small biological samples, including blood and other complex specimens.